Fundraising Fox
Salarius
3 known investors
Find your way into Salarius
Sign up to find every way you can get introduced to Salarius
- Your email: who you already know at Salarius, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Salarius team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms conserved across multiple viruses. Its lead programs are inhaled, self-administered fusion inhibitors for respiratory viruses, including a pan-coronavirus treatment for immunocompromised patients and a combined flu/COVID/RSV antiviral.
Investors · 3
Frequently asked questions
- What does Salarius do?
- Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms conserved across multiple viruses. Its lead programs are inhaled, self-administered fusion inhibitors for respiratory viruses, including a pan-coronavirus treatment for immunocompromised patients and a combined flu/COVID/RSV antiviral.
- Who are Salarius's investors?
- Salarius's investors include Central Texas Angel Network, Cowtown Angels, Dellin Investments.